活化STAT抑制蛋白在乳腺癌发生发展中的研究进展

摘要/Abstract

中图分类号:

R737.9

申扬, 赵毅. 活化STAT抑制蛋白在乳腺癌发生发展中的研究进展[J]. 承德医学院学报, 2023, 40(4): 329-333.

[1] Sung H, Ferlay J, Siegel RL, et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] 刘宗超,李哲轩,张阳,等. 2020全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志,2021,7(2): 1-13.
[3] Owen KL, Brockwell K, Parker BS.JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression[J]. Cancers (Basel), 2019, 11(12):2002.
[4] Taheri M, Oskooei VK, Ghafouri-Fard S.Protein inhibitor of activated STAT genes are differentially expressed in breast tumor tissues[J]. Per Med, 2019, 16(4): 277-285.
[5] Lai Z, Adzigbli L, Chen Q, et al.Identification and Allelic Variants Associated With Cold Tolerance of PmPIAS in Pinctada fucata martensii[J]. Front Physiol, 2021, 12: 634838.
[6] Wang L, Banerjee S.Differential PIAS3 expression in human malignancy[J]. Oncol Rep, 2004, 11(6): 1319-1324.
[7] Brantley EC, Nabors LB, Gillespie GY, et al.Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression[J]. Clin Cancer Res, 2008, 14(15): 4694-4704.
[8] Tirard M, Jasbinsek J, Almeida OF, et al.The manifold actions of the protein inhibitor of activated STAT proteins on the transcriptional activity of mineralocorticoid and glucocorticoid receptors in neural cells[J]. J Mol Endocrinol, 2004, 32(3): 825-841.
[9] Lussier-price M, Mascle XH, Cappadocia L, et al. Characterization of a C-Terminal SUMO-Interacting Motif Present in Select PIAS-Family Proteins[J]. Structure, 2020, 28(5): 573-585.e5.
[10] Jiménez-lara AM, Heine MJ, Gronemeyer H. PIAS3 (protein inhibitor of activated STAT-3) modulates the transcriptional activation mediated by the nuclear receptor coactivator TIF2[J]. FEBS Lett, 2002, 526(1-3): 142-146.
[11] Rabellino A, Andreani C, Scaglioni PP.The Role of PIAS SUMO E3-Ligases in Cancer[J]. Cancer Res, 2017, 77(7): 1542-1547.
[12] Duval D, Duval G, Kedinger C, et al.The 'PINIT' motif, of a newly identified conserved domain of the PIAS protein family, is essential for nuclear retention of PIAS3L[J]. FEBS Lett, 2003, 554(1-2): 111-118.
[13] Zhao Y, He J, Li Y, et al.NUSAP1 potentiates chemoresistance in glioblastoma through its SAP domain to stabilize ATR[J]. Signal Transduct Target Ther, 2020, 5(1): 44.
[14] Chen Z, Zhang Y, Guan Q, et al.Linking nuclear matrix-localized PIAS1 to chromatin SUMOylation via direct binding of histones H3 and H2A.Z[J]. J Biol Chem, 2021, 297(4): 101200.
[15] Sharma A, Khan H, Singh TG, et al.Pharmacological Modulation of Ubiquitin-Proteasome Pathways in Oncogenic Signaling[J]. Int J Mol Sci, 2021, 22(21):11971.
[16] Hung PF, Hong TM, Chang CC, et al.Hypoxia-induced Slug SUMOylation enhances lung cancer metastasis[J]. J Exp Clin Cancer Res, 2019, 38(1): 5.
[17] Chandhoke AS, Chanda A, Karve K, et al.The PIAS3-Smurf2 sumoylation pathway suppresses breast cancer organoid invasiveness[J]. Oncotarget, 2017, 8(13): 21001-21014.
[18] Kukkula A, Ojala VK, Mendez LM, et al.Therapeutic Potential of Targeting the SUMO Pathway in Cancer[J]. Cancers (Basel), 2021, 13(17): 4402.
[19] Heppler LN, Frank DA.Targeting Oncogenic Transcription Factors: Therapeutic Implications of Endogenous STAT Inhibitors[J]. Trends Cancer, 2017, 3(12): 816-827.
[20] Rah B, Rather RA, Bhat GR, et al.JAK/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid Malignancies[J]. Front Pharmacol, 2022, 13: 821344.
[21] Niu GJ, Xu D, Yuan WJ, et al.Protein Inhibitor of Activated STAT (PIAS) Negatively Regulates the JAK/STAT Pathway by Inhibiting STAT Phosphorylation and Translocation[J]. Front Immunol, 2018, 9: 2392.
[22] Wang HQ, Man QW, Huo FY, et al.STAT3 pathway in cancers: Past, present, and future[J]. MedComm (2020), 2022, 3(2): e124.
[23] Bakhmet EI, Tomilin AN.Key features of the POU transcription factor Oct4 from an evolutionary perspective[J]. Cell Mol Life Sci, 2021, 78(23): 7339-7353.
[24] Tolkunova E, Malashicheva A, Parfenov VN, et al.PIAS proteins as repressors of Oct4 function[J]. J Mol Biol, 2007, 374(5): 1200-1212.
[25] Abdelaziz LA, Ebian HF, Harb OA, et al.Clinical significance of cytokeratin 19 and OCT4 as survival markers in non-metastatic and metastatic breast cancer patients[J]. Contemp Oncol(Pozn), 2022, 26(1): 78-87.
[26] Najafzadeh B, Asadzadeh Z, Motafakker Azad R, et al.The oncogenic potential of NANOG: An important cancer induction mediator[J]. J Cell Physiol, 2021, 236(4): 2443-2458.
[27] Biondini M, Kiepas A, El-houjeiri L, et al. HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin[J]. Oncogene, 2022, 41(12): 1701-1717.
[28] Levy C, Sonnenblick A, Razin E.Role played by microphthalmia transcription factor phosphorylation and its Zip domain in its transcriptional inhibition by PIAS3[J]. Mol Cell Biol, 2003, 23(24): 9073-9080.
[29] Fabi F, Asselin E.Expression, activation, and role of AKT isoforms in the uterus[J]. Reproduction, 2014, 148(5): R85-95.
[30] Ghafouri-Fard S, Khanbabapour Sasi A, Hussen BM, et al.Interplay between PI3K/AKT pathway and heart disorders[J]. Mol Biol Rep, 2022,49(10):9767-9781.
[31] Ogata Y, Osaki T, Naka T, et al.Overexpression of PIAS3 suppresses cell growth and restores the drug sensitivity of human lung cancer cells in association with PI3-K/Akt inactivation[J]. Neoplasia, 2006, 8(10): 817-825.
[32] Jiang W, Rixiati Y, Huang H, et al.Asperolide A prevents bone metastatic breast cancer via the PI3K/AKT/mTOR/c-Fos/NFATc1 signaling pathway[J]. Cancer Med, 2020, 9(21): 8173-8185.
[33] Hua Y, Camarco DP, Strock CJ, et al.High Content Positional Biosensor Assay to Screen for Compounds that Prevent or Disrupt Androgen Receptor and Transcription Intermediary Factor 2 Protein-Protein Interactions[J]. Methods Mol Biol, 2018, 1683: 211-227.
[34] Sundvall M, Korhonen A, Vaparanta K, et al.Protein inhibitor of activated STAT3 (PIAS3) protein promotes SUMOylation and nuclear sequestration of the intracellular domain of ErbB4 protein[J]. J Biol Chem, 2012, 287(27): 23216-23226.
[35] 蒋蒙蒙. miR-9/miR-181a为核心的ceRNA网络在IL-6/STAT3信号通路促进乳腺癌eMDSCs生成和免疫抑制活性中的调控研究[D]. 天津:天津医科大学,2019.
[36] Agboola A, Musa A, Banjo A, et al.PIASγ expression in relation to clinicopathological, tumour factors and survival in indigenous black breast cancer women[J]. J Clin Pathol, 2014, 67(4): 301-306.

活化STAT抑制蛋白在乳腺癌发生发展中的研究进展

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘阿敏, 赵文斌, 陈保平. 过表达环状RNA-103809调节乳腺癌细胞氧化应激和免疫[J]. 承德医学院学报, 2022, 39(6): 455-460.
[2]	胡佳琪, 耿怡丹, 张玺, 任悦菲, 刘克温, 田建丽. 个案管理模式在乳腺癌患者中的应用研究进展[J]. 承德医学院学报, 2022, 39(2): 159-162.
[3]	于金正, 赵润泽, 魏宇辰, 柳佳欣, 李晓菊, 张存. 外泌体在乳腺癌发生发展中的作用[J]. 承德医学院学报, 2021, 38(6): 513-517.
[4]	林美红, 张玮琳, 谢碧珊. 优质护理对乳腺癌患者术后生活质量和满意度的影响[J]. 承德医学院学报, 2021, 38(3): 228-230.
[5]	张娟. 风险护理管理对早期乳腺癌NAC根治术后即刻乳房再造的作用[J]. 承德医学院学报, 2021, 38(3): 231-233.
[6]	任悦菲, 刘克温, 李青, 田建丽. 移动健康对乳腺癌术后患者生活质量影响Meta分析[J]. 承德医学院学报, 2020, 37(6): 529-532.
[7]	钮淋, 刘镭, 程露阳, 许倩, 陈志宏, 乔跃兵. 基于生物信息学筛选三阴性乳腺癌关键基因和通路[J]. 承德医学院学报, 2020, 37(5): 361-368.
[8]	刘春芳, 王孜恒, 芮文科, 黄云侠, 徐莹, 季红敏. 多元化延续护理对乳腺癌术后患者自我护理能力及焦虑抑郁情绪的影响[J]. 承德医学院学报, 2020, 37(5): 398-399.
[9]	田庄, 李晓菊, 罗嘉嘉, 黄平, 郭虎, 高源. 肿瘤相关成纤维细胞在乳腺癌发生发展及耐药中的作用[J]. 承德医学院学报, 2020, 37(5): 410-414.
[10]	刘赛璇, 薛晶, 周丽丽, 赵杨, 申兴斌. 鬼臼苦素对人乳腺癌MCF-7细胞增殖的抑制作用[J]. 承德医学院学报, 2020, 37(1): 5-7.
[11]	郭奕嫱, 徐萌泽, 辛小林, 田建丽, 刘亚莉, 刘洋. 乳房自检态度量表的信效度检验[J]. 承德医学院学报, 2020, 37(1): 82-84.
[12]	魏萌, 司丽娜, 陈磊, 程露阳, 杨松鹤. 瘦素对人乳腺癌MCF-7细胞DMBT1表达的影响^*[J]. 承德医学院学报, 2018, 35(3): 252-253.
[13]	薛晶, 赵杨, 程玉, 徐树蕾, 严鹏, 申兴斌. IGF-1在乳腺癌中的表达与临床意义[J]. 承德医学院学报, 2018, 35(2): 99-101.
[14]	王芸, 陈淑如. 保乳根治术和改良根治术治疗Ⅰ,Ⅱ期乳腺癌的效果和安全性分析^*[J]. 承德医学院学报, 2018, 35(1): 32-34.
[15]	张宝双, 杨国明. 双侧乳腺及甲状腺同时性多原发癌1例[J]. 承德医学院学报, 2017, 34(4): 347-348.